Corticosteroid Reduction in COPD

• Status: Completed
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study explores whether patients hospitalized with chronic obstructive pulmonary disease (COPD) exacerbation may have fewer days with prednisolone and with the same treatment effect by controlling the treatment by daily measurements of eosinophils.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark
• Treatments: Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion criteria:

• Patients hospitalized with AECOPD

• Age ≥ 40 years

• Spirometry-verified COPD (defined as FEV1 / FVC ≤ 70%)

• Chronic Obstructive Lung Disease (GOLD) class C or D

• Inclusion within 24 hours after admission

Exclusion criteria:

• Known with a diagnosis of asthma

• Life expectancy less than 30 days

• Serious exacerbation requiring invasive ventilation or admission to ICU

• Allergy to systemic corticosteroids

• Severe mental illness, which is not controlled by medication

• People who are detained under the act on the use of coercion in psychiatry

• Severe language problems or inability to provide written informed consent

• Pregnancy and lactation

• Systemic fungal infections